Research Explained

Can Genetically Modified Mosquitoes Actually Stop Malaria, and Why Did a Government Just Shut the Trial Down?

On 11 August 2025, researchers at Burkina Faso's Institut de Recherche en Sciences de la Sante released around 16,000 genetically modified mosquitoes into a village in the country's Western Region, the first release of its kind on the African continent. Seven days later, the government ordered the entire programme shut down.

Anopheles gambiae, one of the species targeted by Target Malaria. CDC/James D. Gathany, public domain.

Abdoulaye Diabate has spent more than a decade on one question: can a mosquito species be engineered so its population gradually collapses, to stop the disease it carries? Malaria itself is caused by a parasite, not the mosquito. A female Anopheles picks the parasite up from one infected person's blood and passes it to the next person she bites. Diabate heads medical entomology at IRSS and is principal investigator for Target Malaria's local team, which released Africa's first genetically modified mosquitoes in 2019. On 11 August 2025, his team took the next step, releasing around 16,000 modified males into Souroukoudingan village.

Seven days later, authorities ordered the entire programme shut down.

Why are scientists trying this at all?

The tools that got the world this far are losing ground: eight countries have reported resistance to artemisinin, the frontline malaria drug, and insecticide resistance is blunting the bed nets and sprays behind most progress made since 2000. "The red lights are flashing again," said Dr Martin Fitchet, chief executive of the Medicines for Malaria Venture, in December 2025. Genetically modified mosquitoes are among the few tools in development that do not depend on a drug or insecticide still working.

How do you engineer a mosquito to stop malaria?

Target Malaria's mosquitoes are built to break the ordinary rules of inheritance.

The August release used only the milder, self-limiting strain; the X-shredder remains under laboratory development and was not part of what went into the village. Target Malaria's work targets three near-identical species, Anopheles coluzzii, gambiae and arabiensis, all major malaria carriers across West Africa.

Had this actually been approved as safe?

By the project's own account, yes. The IRSS team has operated in Burkina Faso since 2012 and complied throughout with national law, Target Malaria says, and the July 2025 release was authorised by three separate regulators after community consultation in Souroukoudingan itself. Jonathan Kayondo, principal investigator for Target Malaria's Uganda programme, later called the reversal "surprising, because Burkina Faso scientists had gone through all the regulatory approvals."

What happened on 11 August 2025?

Though 16,000 sounds large, Target Malaria calls it small-scale against the village's existing wild population. Researchers were measuring how the modified males survive, disperse and compete for mates, not cutting malaria cases straight away, and the release went "in accord with terms and conditions" of its permits, Target Malaria says. On 18 August, authorities requested a suspension, met immediately, IRSS says. On 22 August, the Ministry of Higher Education, Research and Innovation terminated the project outright: facilities sealed, samples destroyed, released mosquitoes killed with insecticide.

Why did the government shut it down a week later?

Neither Target Malaria nor Burkinabe authorities have given a detailed public explanation, pointing only to unspecified national interests. What is clear is the speed: a project cleared by three regulators the previous month ended within eleven days of its most visible milestone. Reporting since points to two pressures: domestic concerns about ecology and consent, and international scientific criticism of the technology.

Is the underlying science actually settled?

No, and researchers involved say so themselves. Andrea Crisanti of Imperial College London, one of the strain's designers, has co-authored work acknowledging significant defects in the second-phase gene-drive strain. Biologist Christophe Boete argues that modifying an entire species complex assumes "only beneficial outcomes," "scientifically misleading" given how little is known about what fills the gap once a population collapses. A third critique, from the German group Testbiotech, targets control rather than biology: donor-funded research can leave African researchers with limited say over trials on their own soil. Target Malaria points to its own stepwise order, cautious strain first, as the safeguard against exactly these concerns.

What is happening with gene drive mosquitoes elsewhere?

Uganda felt the most immediate cost: Kayondo's team had planned to draw on Burkina Faso's field data for its own release, and with that pipeline cut off, its path forward now runs slower and more expensively. Tanzania's Transmission Zero consortium, led by Dr Dickson Wilson Lwetoijera at the Ifakara Health Institute with Imperial College London, takes a different route entirely: modifying Anopheles gambiae to carry antimalarial molecules from frogs and honeybees, so the mosquitoes still bite but can no longer support the parasite. Published in Nature on 11 December 2025, its results came from blood drawn from Tanzanian children with active infections, which the modified mosquitoes largely resisted. "The first time a genetically modified, gene-drive compatible mosquito strain has been developed in Africa, by African scientists," Lwetoijera called it. Everything has stayed in containment; Imperial's Dr Nikolai Windbichler said the goal was to "move at the right speed, not too fast, so that everyone is on board." Ghana's programme, with the University of Ghana and Oxford, is earlier still, ecological studies only, no field trial date public.

One approach reached an open field within days, then was shut down within a fortnight. Another has spent years in containment before even applying to leave it. IRSS says it remains "ready to cooperate" with Burkinabe authorities, though no timeline for resuming is public this year. Which strategy reaches an open field first is now a decision for regulators, not scientists.

Institutions in this article: Institut de Recherche en Sciences de la Sante, Burkina Faso; Target Malaria; Imperial College London; Ifakara Health Institute, Tanzania; National Institute for Medical Research, Tanzania; Swiss Tropical and Public Health Institute; University of Ghana; University of Oxford.

Frequently Asked Questions